MediciNova, Inc. is a promising startup in the pharmaceutical industry, established in 2018 by experienced entrepreneurs. The company, operating primarily in Biotechnology, Health Care, Life Sciences, and Pharmaceutical sectors, has shown significant growth since its inception. Its focus on in-licensing, development, and commercialization of pain medications exhibits its commitment to addressing unmet medical needs. With a recent $25.00M post-IPO debt investment on 01 August 2023, MediciNova, Inc. has attracted noteworthy investors such as Perceptive Advisors, Tybourne Capital Management, Alger, and Farallon Capital Management. This investment reflects the confidence of these influential investors in the company's vision and potential for future success.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $25.00M | 4 |
|
01 Aug 2023 |
| Post-IPO Equity | $40.00M | - | 29 Oct 2020 | |
| Venture Round | $5.76M | - | 27 Nov 2018 |
No recent news or press coverage available for MediciNova, Inc..
We care about your data, and we'd love to use cookies make your experience better.
